These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 30208970)

  • 1. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
    J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.
    Dai Y; Siemann DW
    BMC Cancer; 2012 May; 12():198. PubMed ID: 22639908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
    Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF
    Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
    J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.
    Imura Y; Nakai T; Yamada S; Outani H; Takenaka S; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
    Cancer Sci; 2016 Dec; 107(12):1867-1876. PubMed ID: 27779808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
    Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
    Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
    Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
    J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
    Kentsis A; Reed C; Rice KL; Sanda T; Rodig SJ; Tholouli E; Christie A; Valk PJ; Delwel R; Ngo V; Kutok JL; Dahlberg SE; Moreau LA; Byers RJ; Christensen JG; Vande Woude G; Licht JD; Kung AL; Staudt LM; Look AT
    Nat Med; 2012 Jul; 18(7):1118-22. PubMed ID: 22683780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
    Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
    Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
    Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.